Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Short-course isoniazid + rifapentine regimens for tuberculosis infection (9H vs 3HP vs 1HP)
ChiCTR2400089027Phase 4Not yet recruiting
- Sponsor
- Shenzhen Third People's Hospital
- Start
- Aug 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of isoniazid and rifapentine in Tuberculosis (TB) and latent tuberculosis infection (LTBI) (3 arms), sponsored by Shenzhen Third People's Hospital. Primary endpoints: Incidence rate of adverse events at all levels, Cumulative incidence rate of tuberculosis and 2 more. Planned start Aug 2024; status: not yet recruiting.
02
Drugs
isoniazidrifapentine
03
Conditions
Tuberculosis (TB)latent tuberculosis infection (LTBI)
Beyond the preview
Go deeper on ChiCTR2400089027.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400089027.